Methyl iodide → 2-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)propan-2-ol
反応式
[Cl:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([C:11]([OH:14])([CH3:13])[CH3:12])[NH:8]2)=[C:4]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)[N:3]=1.I[CH3:22]>>[Cl:1][C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([C:11]([OH:14])([CH3:13])[CH3:12])[N:8]2[CH3:22])=[C:4]([N:15]2[CH2:16][CH2:17][O:18][CH2:19][CH2:20]2)[N:3]=1参加物
3
実験手順
2-(2-Chloro-6-morpholino-9H-purin-8-yl)propan-2-ol (100 mg) was treated with iodomethane via General Procedure C to give crude intermediate 2-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)propan-2-ol which was treated with 2-aminopyrimidine-5-boronic acid, pinacol ester via General Procedure A and purified via reverse phase HPLC to give 44 mg of 130 as a white solid. MS (Q1) 371.2 (M)+.
出典と根拠
- ORDレコード
- ord-dd5fbbba8b2d4ce3b98a976f14963931
- 出典データセット
- uspto-grants-2012_04
- 特許番号
- US08158624B2
反応ノート
読み込み中…